Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
40.12
-1.82 (-4.34%)
Nov 17, 2026, 3:00 PM CST
SHA:688513 Revenue
Chengdu Easton Biopharmaceuticals had revenue of 331.55M CNY in the quarter ending September 30, 2026, a decrease of -9.09%. This brings the company's total for the last twelve months to 1.30B, down -1.98% year-over-year. In the year 2025, Chengdu Easton Biopharmaceuticals had annual revenue of 1.33B, down -1.36%. That makes Chengdu Easton Biopharmaceuticals the 17,679th largest company in the world by revenue and 3,221st in China.
Revenue (ttm)
1.30B
Revenue Growth
-1.98%
P/S Ratio
5.32
Revenue / Employee
880.21K
Employees
1,416
Market Cap
6.95B
Revenue by Geography
- East China 476.68M 35.9%
- Southwest Region 253.79M 19.1%
- Northern China 212.86M 16.0%
- Southern China 164.98M 12.4%
- Central China Region 92.99M 7.0%
- Northeast China Region 58.86M 4.4%
- Northwestern Region 37.56M 2.8%
- Overseas Regions 31.38M 2.4%
Fiscal year ended Dec 31, 2025 See the full SHA:688513 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.33B | -18.37M | -1.36% |
| Dec 31, 2024 | 1.35B | 232.63M | 20.82% |
| Dec 31, 2023 | 1.12B | -53.39M | -4.56% |
| Dec 31, 2022 | 1.17B | 147.58M | 14.43% |
| Dec 31, 2021 | 1.02B | 101.02M | 10.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.13B |
| Novogene | 2.30B |
| Jiangxi Fushine Pharmaceutical | 1.97B |
| Aurisco Pharmaceutical | 1.67B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.43B |
| Vcanbio Cell & Gene Engineering Corp., | 1.38B |
| Bio-Thera Solutions | 1.05B |
| Daan Gene | 776.43M |